Iranian journal of basic medical sciences · 2026
The role of H3K18la in regulating CDKN1B-mediated autophagy in neuropathic pain.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ou Xiao-Jing, Zhu Feng-Ting, Zhang Man-Yan, Li Lang, Zhao Wei-Cheng, Wen Xian-Jie
Аннотация
OBJECTIVES: To investigate the role of histone lactylation in chronic constriction injury (CCI)-induced neuropathic pain and elucidate its mechanism.
MATERIALS AND METHODS: SD rats were assigned to Normal (n=6), CCI (n=24), and CCI+oxamate (n=24) groups; the latter two were subdivided into four time points (days 1, 4, 7, 14; n=6 each). Oxamate (300 mg/kg, IP) was given on days 0, 2, 4, 6, 10, and 12 to inhibit glycolysis. Pain behaviors were assessed. Spinal lactate and histone H3 lysine 18 lactylation (H3K18la) were measured. CUT&Tag on day 14 identified CDKN1B as an H3K18la target. A separate CDKN1B siRNA group received intrathecal siRNA on days 6, 8, 10, and 12 under oxamate treatment. Spinal IL-6, TNF-α, IL-10, Beclin-1, and LC3-II/LC3-I ratio were detected.
RESULTS: CCI elevated spinal lactate, H3K18la, and pain, with increased inflammation compared with Normal. Oxamate reduced lactate, global H3K18la, pain, and inflammation. CUT&Tag showed higher H3K18la enrichment at the CDKN1B promoter in the oxamate group, along with up-regulated CDKN1B, Beclin-1, and the LC3-II/I ratio. CDKN1B knockdown suppressed these autophagy markers and exacerbated pain and inflammation.
CONCLUSION: CCI causes spinal lactate accumulation and global H3K18la up-regulation, thereby exacerbating pain and inflammation. Oxamate lowers global H3K18la but specifically increases H3K18la enrichment at the CDKN1B promoter, up-regulating CDKN1B to activate autophagy and alleviate neuropathic pain.
MATERIALS AND METHODS: SD rats were assigned to Normal (n=6), CCI (n=24), and CCI+oxamate (n=24) groups; the latter two were subdivided into four time points (days 1, 4, 7, 14; n=6 each). Oxamate (300 mg/kg, IP) was given on days 0, 2, 4, 6, 10, and 12 to inhibit glycolysis. Pain behaviors were assessed. Spinal lactate and histone H3 lysine 18 lactylation (H3K18la) were measured. CUT&Tag on day 14 identified CDKN1B as an H3K18la target. A separate CDKN1B siRNA group received intrathecal siRNA on days 6, 8, 10, and 12 under oxamate treatment. Spinal IL-6, TNF-α, IL-10, Beclin-1, and LC3-II/LC3-I ratio were detected.
RESULTS: CCI elevated spinal lactate, H3K18la, and pain, with increased inflammation compared with Normal. Oxamate reduced lactate, global H3K18la, pain, and inflammation. CUT&Tag showed higher H3K18la enrichment at the CDKN1B promoter in the oxamate group, along with up-regulated CDKN1B, Beclin-1, and the LC3-II/I ratio. CDKN1B knockdown suppressed these autophagy markers and exacerbated pain and inflammation.
CONCLUSION: CCI causes spinal lactate accumulation and global H3K18la up-regulation, thereby exacerbating pain and inflammation. Oxamate lowers global H3K18la but specifically increases H3K18la enrichment at the CDKN1B promoter, up-regulating CDKN1B to activate autophagy and alleviate neuropathic pain.